Prostate Cancer Trial Composite PSA/Bone Scan Endpoint Suggested By FDA
Executive Summary
FDA could consider an endpoint for prostate cancer trials that combines PSA kinetics and bone scan results, FDA Office of Cellular, Tissue & Gene Therapies Oncology Group Leader Steven Hirschfeld, MD/PhD, suggested